Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2019.1640348
Abstract: Abstract Background: Tildrakizumab is a high-affinity, humanized, IgG1 κ, anti-interleukin-23 monoclonal antibody approved for moderate-to-severe plaque psoriasis. Objectives: This analysis examined whether tildrakizumab’s week-28 efficacy can be sustained or improved to week 52. Methods: Psoriasis… read more here.
Keywords: week; pasi responses; week pasi; tildrakizumab ... See more keywords